AI assistant
Sending…
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2018
Dec 21, 2018
33148_dirs_2018-12-21_3af45938-c5be-4761-a6b0-c8701644dea8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2018-12-20
Reporting Person: Patel Kinnari (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-12-20 | Common Stock | M | 55869 | $1.21 | Acquired | 55869 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-12-20 | Stock Option (Right to Buy) | $1.21 | M | 55869 | Acquired | 2026-04-18 | Common Stock (55869) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5675 | Indirect |
| Common Stock | 94927 | Indirect |
Footnotes
F1: The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.
F2: This option represents a right to purchase a total of 167,607 shares of the Issuer's Common Stock 56,072 of which became fully vested and exercisable on April 18, 2017, with the remaining 111,535 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
More from ROCKET PHARMACEUTICALS, INC.
Merger & Acquisition
2026
May 28
Regulatory Filings
2026
May 21
Regulatory Filings
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 6
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 27
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Feb 26
Annual Report
2026
Feb 26
Director's Dealing
2026
Feb 20